Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS.

Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.

2.

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.

Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K.

Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.

3.

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

PMID:
21990393
4.

Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.

Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS.

J Clin Oncol. 2009 Dec 10;27(35):6027-32. doi: 10.1200/JCO.2009.23.8592. Epub 2009 Nov 2.

PMID:
19884539
5.

Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.

Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, Sun Z, Zhang X, Li Z, Yan J, Chang Y, Lu L, Qin B, Li X, Wen J, Zhang M.

Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13.

PMID:
24923454
6.

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.

Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, Kim WS.

Ann Hematol. 2015 Jan;94(1):71-8. doi: 10.1007/s00277-014-2171-4. Epub 2014 Aug 2.

PMID:
25082384
7.

Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).

Kim M, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS.

Ann Hematol. 2015 Mar;94(3):437-44. doi: 10.1007/s00277-014-2228-4. Epub 2014 Oct 11.

PMID:
25300500
8.

A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.

Ji J, Liu T, Xiang B, Liu W, He C, Chen X, Li J, Chang H, Dai Y, Dong T.

Leuk Lymphoma. 2014 Dec;55(12):2955-7. doi: 10.3109/10428194.2014.907894. Epub 2014 May 6. No abstract available.

PMID:
24679007
9.

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.

Kim BS, Kim DW, Im SA, Kim CW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK.

Ann Oncol. 2009 Jan;20(1):121-8. doi: 10.1093/annonc/mdn551. Epub 2008 Aug 5.

PMID:
18684695
10.

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9. doi: 10.1182/blood-2010-09-307454. Epub 2010 Dec 1.

11.

High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.

Ding H, Chang J, Liu LG, Hu D, Zhang WH, Yan Y, Ma LY, Li ZC, Ma YJ, Hao SG, Tao R.

Int J Hematol. 2015 Aug;102(2):181-7. doi: 10.1007/s12185-015-1809-x. Epub 2015 May 22.

PMID:
25997870
12.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
13.

Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.

Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K.

J Clin Oncol. 2009 Nov 20;27(33):5594-600. doi: 10.1200/JCO.2009.23.8295. Epub 2009 Oct 5.

PMID:
19805668
14.

Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.

Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R.

Clin Cancer Res. 2012 Aug 1;18(15):4183-90. Epub 2012 Jun 6.

15.

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F.

Eur J Haematol. 2003 Apr;70(4):219-24.

PMID:
12656744
16.

Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.

Suzuki R.

Int J Hematol. 2010 Dec;92(5):697-701. doi: 10.1007/s12185-010-0726-2. Epub 2010 Dec 1. Review.

PMID:
21116747
17.

Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L.

Cancer. 2012 Jul 1;118(13):3294-301. doi: 10.1002/cncr.26629. Epub 2011 Dec 2.

18.

Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.

Guo Y, Lu JJ, Ma X, Wang B, Hong X, Li X, Li J.

Oral Oncol. 2008 Jan;44(1):23-30. Epub 2007 Feb 15.

PMID:
17306611
19.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.

Ai Zheng. 2005 Apr;24(4):465-9. Chinese.

PMID:
15820071
20.

Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Yang L, Liu H, Xu XH, Wang XF, Huang HM, Shi WY, Jiang SH.

Med Oncol. 2013 Dec;30(4):720. doi: 10.1007/s12032-013-0720-7. Epub 2013 Sep 24.

PMID:
24062259

Supplemental Content

Support Center